Bäckryd, Emmanuel
Themistocleous, Andreas
Larsson, Anders
Gordh, Torsten
Rice, Andrew S. C.
Tesfaye, Solomon
Bennett, David L.
Gerdle, Björn
Funding for this research was provided by:
E. Bäckryd reports grants from ALF Grants, Region Östergötland, and from NEURO Sweden
Linköping University
Article History
Received: 7 November 2023
Accepted: 1 July 2024
First Online: 24 July 2024
Competing interests
: A.T., A.L., E.B., B.G., and T.G. have no conflict of interest to declare. Andrew SC Rice (ASCR) was a Principal Investigator/director of the Wellcome Trust funded London Pain Consortium through which the PiNS study was funded. ASCR declares the following interests unrelated to this manuscript occurring in last 36 months: Employee Imperial College London. Hon Consultant Chelsea and Westminster Hospital NHS Foundation Trust. ASCR undertakes consultancy and advisory board work for Imperial College Consultants- in the last 36 months this has included remunerated work for: Confo, Combigene, Vertex, Novartis, Orion, Shanghai SIMR Biotech & Science Practice (Wellcome Trust). ASCR is named as an inventor on patents: Rice A.S.C., Vandevoorde S. and Lambert D.M Methods using N-(2-propenyl)hexadecanamide and related amides to relieve pain. WO 2005/079771. Okuse K. et al. Methods of treating pain by inhibition of vgf activity EP13702262.0/ WO2013 110945. Member Joint Committee on Vaccine and Immunisation- varicella sub-committee. Analgesic Clinical Trial Translation: Innovations, Opportunities, and Networks (ACTTION) steering committee member. Medicines and Healthcare products Regulatory Agency (MHRA), Commission on Human Medicines—Neurology, Pain & Psychiatry Expert Advisory Group. Grants and studentships—UKRI (Medical Research Council & BBSRC), Versus Arthritis, Alan and Sheila Diamond Trust, Royal British Legion, European Commission, Ministry of Defence, Dr Jennie Gwynn Bequests, The British Pain Society, Royal Society of Medicine. Royal College of Anaesthetists—Heritage and Archives Committee (2020—date). Lecture honoraria: MD Cancer Cancer Center -2021, University California San Francisco. CSF12th Pediatric Pain Master Class (USA) Dec 2021, Bioevents – Controversies in Neuropathic pain – 2021, Royal Marsden Hospital 2019, Indonesian Neurological Association Pain Study Group International Lecture Series Donated to (Association of Southeast Asian Pain Societies (ASEAPS) –Oct 2022, Malaysian Society of Anaesthesiologists – July 2022, Siriraj Hospital Bangkok international relations programme- visiting Professorship Nov 2022 – used for expenses. Royal Pharmaceutical Society- British National Formulary- ongoing. International Association Study of Pain: Executive Committee (President-elect). David L Bennett (DLB) was a Principal Investigator/director of the Wellcome Trust funded London Pain Consortium through which the PiNS study was funded. DLB declares the following interests unrelated to this manuscript occurring in last 36 months: DLB is a member of the NeupSIG executive committee. DLB has received grant funding from UKRI, Lilly, AstraZeneca, Wellcome, EU and Diabetes UK. DLB has acted as a consultant in the last 2 years for AditumBio, Amgen, Biointervene, Bristows, LatigoBio, GSK, Ionis, Lexicon therapeutics, Lilly, Neuvati, Olipass, Regeneron, Replay and Theranexus on behalf of Oxford University Innovation. DLB has been named on a patent ‘a method for the treatment or prevention of pain, or excessive neuronal activity, or epilepsy’ Application No. 16/337,428. Solomon Tesfaye has received: honoraria from Procter & Gamble, Viatris, Grunenthal, Novo Nordisk, Pfizer, Merck, Eva Pharma, Hikma, Astellas Pharma, Abbott, AstraZeneca, Berlin-Chemie, Worwag Pharma, Nevro, Haisco Pharmaceutical Group, for educational meetings; consultancy fees for advisor board membership from Angelini, Bayer, GSK, Worwag Phrama and Nevro; research equipment donated to Sheffield Teaching Hospitals from Impeto Medical and Neurometrix; and unrestricted, competitive research grants from Viatris and Procter and Gamble.